Related Experiment Video
Updated: Aug 14, 2026
06:08
A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
Molecular markers for malignancy in adrenocortical tumors
1Laboratoire d'Explorations Fonctionnelles, Endocriniennes, Hôpital Trousseau, Paris, France.
Hormone Research
|January 1, 1997
Summary
Genetic changes like 17p13 loss of heterozygosity (LOH) and 11p15 abnormalities are common in adrenocortical tumors. These findings may aid in distinguishing benign from malignant tumors.
Area of Science:
- Endocrinology
- Oncology
- Genetics
Background:
- The pathophysiology of sporadic adrenocortical tumors remains poorly understood.
- Differentiating benign from malignant adrenocortical tumors using conventional histology is challenging.
Purpose of the Study:
- To investigate genetic alterations in adrenocortical tumors.
- To determine if specific genetic changes correlate with tumor malignancy.
Main Methods:
- Analysis of 38 adrenocortical tumors (23 benign, 15 malignant).
- Testing for loss of heterozygosity (LOH) at 17p13.
- Assessing abnormalities in the 11p15 region, including uniparental disomy (UPD) and IGF II gene overexpression.
Main Results:
- Loss of heterozygosity at 17p13 was observed in a significant portion of tumors.
- Abnormalities in the 11p15 region, including UPD and IGF II gene overexpression, were frequent.
- These genetic changes were detected in 40% of the analyzed adrenocortical tumors.
- The identified genetic alterations were associated with the malignant phenotype of the tumors.
Conclusions:
- Genetic alterations such as 17p13 LOH and 11p15 abnormalities (UPD, IGF II overexpression) are prevalent in adrenocortical tumors.
- These genetic markers show potential for improving the diagnostic evaluation of adrenocortical tumors, aiding in distinguishing malignant from benign types.
